Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Voices

FDA Voices Home
          News & Events
          FDA Newsroom
          FDA Voices
          FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine DevelopmentFDA Voices FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              a row of seven small glass medical vials containing clear liquid and a medical syringe used for injecting vaccines*By: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research*

Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed to it. They have been highly effective in preventing a whole range of serious infectious diseases. But there is currently no vaccine available to protect the public from the highly contagious coronavirus known as SARS-CoV-2 that is spreading globally, causing the respiratory disease COVID-19, and we know that is a major global public health concern.

CBER Director, Peter Marks, M.D., Ph.D.
Peter Marks, M.D., Ph.D.That’s why commercial vaccine manufacturers and other entities are aggressively working to develop vaccine candidates. So far, they’ve been able to accelerate the development timelines to enter into initial clinical trials in humans (Phase 1 studies) as expeditiously as possible.

The global regulatory community is doing all that it can to help advance these efforts. On March 18, the U.S Food and Drug Administration and the European Medicines Agency (EMA) jointly chaired the first global regulators meeting to discuss regulatory strategies to facilitate the development of SARS-CoV-2 vaccines. The purpose of this discussion was to promote, to the extent possible, regulatory convergence with the goal of streamlining global SARS-CoV-2 vaccine development.

The FDA’s Europe Office organized the audio/video conference, which was conducted under the auspices of the International Coalition of Medicines Regulatory Authorities—an international executive-level coalition that brings together key regulators from every region of the world to facilitate access to safe, effective, high-quality products. More than 60 experts representing 25 agencies and 17 countries participated in the meeting, as well as the World Health Organization.

Regulators focused on the preclinical data needed to demonstrate safety and thus support proceeding to first-in-human clinical trials. Their discussions included the need for data evaluating the theoretical risk for vaccine-induced disease enhancement, which is when vaccinated individuals who are subsequently infected with a virus develop disease that is worse than if they had not received a vaccine at all. Regulators acknowledged the urgency of proceeding to human clinical trials with SARS-CoV-2 candidate vaccines in light of the current COVID-19 pandemic, yet stressed the importance of preclinical and clinical risk mitigation strategies so that those enrolled in clinical trials are not exposed to unreasonable risk. As work progresses, frequent communication among global regulators regarding progress of clinical trials is essential.

This first global regulators discussion was a critically important exchange of information and views. The FDA and the EMA intend to convene additional meetings with other global regulators to enable sharing of data from upcoming clinical trials to help ensure global preparedness and promote regulatory convergence, with the goal of streamlining global SARS-CoV-2 vaccine development.

The FDA remains steadfast in helping to foster the development of safe and effective medical products to address this pandemic. Agency staff are working around the clock to facilitate SARS-CoV-2 prevention and treatment options as part of the agency’s response to this outbreak.

Additional Resources: Vaccine Product Approval Process

                                                                                  Content current as of:
      03/23/2020
              
              
Regulated Product(s)
		 Biologics
			  			     			  						              
			
			 
			  VaccinesFDA Voices
 FDA Voices Email
                        Subscribe to receive FDA Voices email notifications
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop